High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma-a systematic review

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Peinemann, Frank ^a   Kröger, Nicolaus ^b   Bartel, Carmen ^a   Grouven, Ulrich ^a,c   Pittler, Max ^d   Erttmann, Rudolf ^b   Kulig, Michael ^a,e  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Federal Joint Committee of the German Health Care System (G BA)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TOXICITY; BONE MARROW METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFANT; KIDNEY TUBULE ACIDOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RHABDOMYOSARCOMA; SEPSIS; SYSTEMATIC REVIEW; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; MULTIMODALITY CANCER THERAPY; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM METASTASIS; PROGNOSIS; RHABDOMYOSARCOMA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952020083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017127     Document Type: Article

References (110)

1. Sobin LH, Gospodarowicz MK, Wittekind C, (2009) UICC: TNM classification of malignant tumors. Oxford Wiley-Blackwell.
2. Weiss SW, Goldblum JR, (2001) Enzinger and Weiss's soft tissue tumors. Saint Louis Mosby.
3. Parham DM, Ellison DA, (2006) Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 130: 1454-1465.
4. Gurney JG, Young JL, Roffers SD, Smith MA, Bunin GR, (1999) Soft tissue sarcomas. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995 (SEER Pediatric Monograph) National Cancer Institute, SEER Program.NIH Pub. No. 99-4649 Bethesda National Cancer Institute pp. 111-124.
5. Miller RW, Young JL Jr, Novakovic B, (1995) Childhood cancer. Cancer 75: 395-405.
6. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, et al. (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78-84.
7. Banna GL, Simonelli M, Santoro A, (2007) High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: A critical review. Curr Stem Cell Res Ther 2: 65-82.
8. Ladenstein R, Philip T, Gardner H, (1997) Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr 9: 55-69.
9. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D, (2007) Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: Focus on increasing use of unrelated donors. Bone Marrow Transplant 39: 71-87.
10. Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, et al. (2006) High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 17: 1479-1488.
11. Woods WG, (1999) Myeloablative therapy followed by stem cell rescue for pediatric solid tumors: A non-transplanter's perspective. Canc Res Ther Contr 9: 95-99.
12. Bonnet D, Dick JE, (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
13. Sanchez-Garcia I, Vicente-Duenas C, Cobaleda C, (2007) The theoretical basis of cancer-stem-cell-based therapeutics of cancer: Can it be put into practice? BioEssays 29: 1269-1280.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
16. (2005) Glossary of Terms in The Cochrane Collaboration (Version 4.2.5). The Cochrane Collaboration.
17. (2006) MeSH Tree Number Changes- 2007 MeSH.September 14, 2006. Bone Marrorw Transplantation, deleted MN:E4.936.225.687.155 Bethesda National Library of Medicine.
18. Tybaert S, (2007) MeSH® Data Changes- 2008. 359 NLM Tech Bull.
19. Ek ETH, Choong PFM, (2006) The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 6: 225-237.
20. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M, et al. (2008) Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer 112: 1197-1205.
21. (2010) Clinical Trials. Bethesda National Institutes of Health (NIH).
22. (2010) International Standard Randomised Controlled Trial Number (ISRCTN) Register. London Current Controlled Trials Ltd.
23. (2010) United Kingdom Clinical Research Network's (UKCRN) Portfolio Database. London National Institute for Health Research (NIHR).
24. (2010) Clinical Trials, Physician Data Query (PDQ). Bethesda National Cancer Institute (NCI).
25. (2010) Ongoing studies, STWP Solid Tumor Working Party. London EBMT European Group for Blood and Marrow Transplantation.
26. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
27. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
28. Higgins JPT, Green S, eds. (2009) Section 9.4.3 A generic inverse-variance approach to meta-analysis. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration.
29. Higgins JPT, Green S, eds. (2009) Section 7.7.7 Data extraction for estimates of effects. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration.
30. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
32. Higgins JPT, Green S, eds. (2009) Section 13.6.2.4 When pooling is judged not to be appropriate. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration.
33. Kaplan EL, Meier P, (1958) Non parametric estimation from incomplete observations. Am Stat Assoc 53: 457-481.
34. Cancer Therapy Evaluation Program (CTEP) (2009) Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Bethesda, MD National Cancer Institute (NCI).
35. Higgins JPT, Green S, eds. (2009) Section 13.5. Assessing risk of bias in non-randomized studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration.
36. Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, et al. (1999) High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17: 2796-2803.
37. Hosoi H, Teramukai S, Matsumoto Y, Tsuchiya K, Iehara T, et al. (2007) A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol 12: 137-145.
38. Klingebiel T, Boos J, Beske F, Hallmen E, Int-Veen C, et al. (2008) Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 50: 739-745.
39. Bisogno G, Ferrari A, Prete A, Messina C, Basso E, et al. (2009) Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer 45: 3035-3041.
40. Yamada K, Takahashi M, Ogura M, Kagami Y, Taji H, et al. (2007) High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas. Bone Marrow Transplant 39: 471-476.
41. Bagnulo S, Perez DJ, Barrett A, (1985) High dose melphalan and autologous bone marrow transplantation for solid tumours of childhood. Eur Paediatr Haematol Oncol 2: 129-133.
42. Bernbeck B, Bahci S, Meisel R, Troeger A, Schonberger S, et al. (2007) Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS). Klin Padiatr 219: 318-322.
43. Bien E, Stachowicz-Stencel T, Sierota D, Polczynska K, Szolkiewicz A, et al. (2007) Sarcomas in children with neurofibromatosis type 1- Poor prognosis despite aggressive combined therapy in four patients treated in a single oncological institution. Childs Nervous Sys 1147-1153.
44. Chan KW, Rogers PC, Fryer CJ, (1991) Breast metastases after bone marrow transplantation for rhabdomyosarcoma. Bone Marrow Transplant 7: 171-172.
45. Ekert H, Tiedemann K, Waters KD, Ellis WM, (1984) Experience with high dose multiagent chemotherapy and autologous bone marrow rescue in the treatment of twenty-two children with advanced tumours. Aust Paediatr J 20: 195-201.
46. Emminger W, Emminger-Schmidmeier W, Peters C, Hawliczek R, Hocker P, et al. (1991) Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity? Bone Marrow Transplant 8: 119-123.
47. Endo M, Yokoyama J, Ikawa H, Watanabe K, Ueda M, et al. (1996) Treatment of high-risk solid tumors of childhood with myeloablative chemotherapy and autologous stem cell transplantation: A single institution experience. Oncol Rep 3: 519-525.
48. Engelhardt M, Zeiser R, Ihorst G, Finke J, Muller CI, (2007) High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol 133: 1-11.
49. Fekrat S, Miller NR, Loury MC, (1993) Alveolar rhabdomyosarcoma that metastasized to the orbit. Arch Ophthalmol 111: 1662-1664.
50. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, et al. (2006) Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant 37: 175-181.
51. Hara J, Osugi Y, Ohta H, Matsuda Y, Nakanishi K, et al. (1998) Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant 22: 7-12.
52. Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, et al. (2002) Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer 95: 1354-1365.
53. Kaizer H, Wharam MD, Munoz LL, Johnson RJ, Elfenbein GJ, et al. (1979) Autologous bone marrow transplantation in the treatment of selected human malignancies: The Johns Hopkins Oncology Center Program. Exp Hematol 7: 309-320.
54. Kasper B, Dietrich S, Mechtersheimer G, Ho AD, Egerer G, (2007) Large Institutional Experience with Dose-Intensive Chemotherapy and Stem Cell Support in the Management of Sarcoma Patients. Oncology 73: 58-64.
55. Kasper B, Scharrenbroich I, Schmitt T, Wuchter P, Dietrich S, et al. (2009) Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. Bone Marrow Transplant 45: 1234-1238.
56. Korfel A, Fischer L, Foss HD, Koch HC, Thiel E, (2001) Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature. Bone Marrow Transplant 28: 787-789.
57. Kuroiwa M, Sakamoto J, Shimada A, Suzuki N, Hirato J, et al. (2009) Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome. J Pediatr Surg 44: e31-e35.
58. Kwan WH, Choi PH, Li CK, Shing MK, Chik KW, et al. (1996) Breast metastasis in adolescents with alveolar rhabdomyosarcoma of the extremities: report of two cases. Pediatr Hematol Oncol 13: 277-285.
59. Kwon SY, Won SC, Han JW, Shin YJ, Lyu CJ, (2010) Feasibility of sequential high-dose chemotherapy in advanced pediatric solid tumors. Pediatr Hematol Oncol 27: 1-12.
60. Lafay-Cousin L, Hartmann, Plouvier P, Mechinaud F, Boutard P, et al. (2000) High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study. Bone Marrow Transplant 26: 627-632.
61. Lashkari A, Chow WA, Valdes F, Leong L, Phan V, et al. (2009) Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res 29: 3281-3288.
62. Lucidarme N, Valteau-Couanet D, Oberlin O, Couanet D, Kalifa C, et al. (1998) Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant 22: 535-540.
63. Mitchell PL, Shepherd VB, Proctor HM, Dainton M, Cabral SD, et al. (1994) Peripheral blood stem cells used to augment autologous bone marrow transplantation. Arch Dis Child 70: 237-240.
64. Munoz LL, Wharam M, Kaiser H, Leventhal BG, Ruymann F, (1983) Magna-field irradiation and autologous marrow rescue in the tratment of pediatric solid tumors. Int J Radiat Oncol Biol Phys 9: 1951-1954.
65. Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, et al. (2006) Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas. Cancer 106: 1846-1856.
66. Oue T, Kubota A, Okuyama H, Kawahara H, Inoue M, et al. (2003) Megatherapy with hematopoietic stem cell rescue as a preoperative treatment in unresectable pediatric malignancies. J Pediatr Surg 38: 130-133.
67. Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N, (1999) Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 24: 609-615.
68. Ritchie DS, Grigg AP, Roberts AW, Rosenthal MA, Fox RM, et al. (2004) Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. Intern Med J 34: 431-434.
69. Rossbach HC, Lacson A, Grana NH, Barbosa JL, (1999) Duchenne muscular dystrophy and concomitant metastatic alveolar rhabdomyosarcoma. J Pediatr Hematol Oncol 21: 528-530.
70. Saikawa Y, Tone Y, Ikawa Y, Maeba H, Koizumi S, et al. (2006) Hemophagocytic alveolar rhabdomyosarcoma. J Clin Oncol 24: 5783-5784.
71. Sakayama K, Tauchi H, Sugawara Y, Kidani T, Tokuda K, et al. (2008) A complete remission of sclerosing rhabdomyosarcoma with multiple lung and bone metastases treated with multi-agent chemotherapy and peripheral blood stem cell transplantation (PBSCT): a case report. Anticancer Res 28: 2361-2367.
72. Sanz N, de Mingo L, Florez F, Rollan V, (1997) Rhabdomyosarcoma of the biliary tree. Pediatr Surg Int 12: 200-201.
73. Shaw PJ, Pinkerton CR, Yaniv I, (1996) Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours. Bone Marrow Transplant 18: 1043-1047.
74. Walterhouse DO, Hoover ML, Marymont MA, Kletzel M, (1999) High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital. Med Pediatr Oncol 32: 88-92.
75. Williams BA, Williams KM, Doyle J, Stephens D, Greenberg M, et al. (2004) Metastatic rhabdomyosarcoma: a retrospective review of patients treated at the hospital for sick children between 1989 and 1999. J Pediatr Hematol Oncol 26: 243-247.
76. McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, et al. (2010) Outcomes in paediatric metastatic rhabdomyosarcoma: Results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer 46: 1588-1595.
77. Stiff PJ, Agovi MA, Antman KH, Blaise D, Camitta BM, et al. (2010) High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. Biol Blood Marrow Transplant 16: 525-532.
78. Kanabar DJ, Attard-Montalto S, Saha V, Kingston JE, Malpas JE, et al. (1995) Quality of life in survivors of childhood cancer after megatherapy with autologous bone marrow rescue. Pediatr Hematol Oncol 12: 29-36.
79. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, et al. (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7: 1-173.
80. Higgins JPT, Green S, eds. (2009) Section 9.5.2 Identifying and measuring heterogeneity. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration.
81. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS, (2001) Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 23: 272-276.
82. Admiraal R, Van der PM, Kobes J, Kremer LCM, Bisogno G, et al. (2007) High dose chemotherapy for children with stage IV rhabdomyosarcoma (Protocol). Cochrane Database Syst Rev 2007; (3): CD006669 Chichester Wiley.
83. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG, (2004) Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291: 2457-2465.
84. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, et al. (2010) The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 340: c365.
85. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ, (2000) Publication and related biases. Health Technol Assess 4: 1-115.
86. Higgins JPT, Green S, eds. (2009) Section 10.4.1 Funnel plots. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration.
87. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, et al. (1997) Language bias in randomised controlled trials published in English and German. Lancet 350: 326-329.
88. Moher D, Pham B, Lawson ML, Klassen TP, (2003) The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess 7: 1-90.
89. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M, (2002) Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 31: 115-123.
90. Galandi D, Schwarzer G, Antes G, (2006) The demise of the randomised controlled trial: bibliometric study of the German-language health care literature, 1948 to 2004. BMC Med Res Methodol 6: 30.
91. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, et al. (2000) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 18: 3643-3650.
92. Carvajal R, Meyers P, (2005) Ewing's sarcoma and primitive neuroectodermal family of tumors. Hematol Oncol Clin North Am 19: 501-525.
93. Dumontet C, Biron P, Bouffet E, Blay JY, Meckenstock R, et al. (1992) High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 10: 405-408.
94. Elias AD, (1998) High-dose therapy for adult soft tissue sarcoma: dose response and survival. Semin Oncol 25: 19-23.
95. Hale GA, (2005) Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther 5: 835-846.
96. Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, et al. (2004) High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 34: 37-41.
97. Kavan P, Stankova J, Koutecky J, Gajdos P, (1997) High-dose chemotherapy with subsequent autologous stem cell transplantation in children and adolescents for high-risk rhabdomyosarcoma. A 3-year survival outcome. Klinicka Onkol 10: 148-151.
98. Mackall CL, Helman LJ, (2001) High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. J Pediatr Hematol Oncol 23: 266-267.
99. Meyers PA, (2004) High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 16: 120-125.
100. Michon J, Schleiermacher G, (1999) Autologous haematopoietic stem cell transplantation for paediatric solid tumours. Best Pract Res Clin Haematol 12: 247-259.
101. Pinkerton R, Philip T, Bouffet E, Lashford L, Kemshead J, (1986) Autologous bone marrow transplantation in paediatric solid tumours. Clin Haematol 15: 187-203.
102. Reichardt P, (2002) High-dose chemotherapy in adult soft tissue sarcoma. Critical Reviews in Oncology-Hematology 41: 157-167.
103. Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, et al. (2002) High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 41: 129-140.
104. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahman S, Licht T, et al. (2006) Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 71: 32-39.
105. Seeger RC, Reynolds CP, (1991) Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 38: 393-424.
106. Bader JL, Horowitz ME, Dewan R, Watkins E, Triche TJ, et al. (1989) Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure. Radiother Oncol 16: 189-201.
107. Carli M, Colombatti R, Oberlin O, Bisogno G, Treuner J, et al. (2004) European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22: 4787-4794.
108. Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, et al. (1997) Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 19: 227-231.
109. Matsubara H, Makimoto A, Higa T, Kawamoto H, Takayama J, et al. (2003) Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy. Pediatr Hematol Oncol 20: 201-210.
110. Suita S, Noguchi S, Takamatsu H, Mizote H, Nagasaki A, et al. (2005) Clinical characteristics and the prognosis of rhabdomyosarcoma- A report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. Eur Journal Pediatr Surg 15: 409-413.